Advertisement
Table 1 Antibodies used in this study
| (A) Phospho-specific antibodies | ||||
| Substrate | poY location | Mol mass (kDa) | Co.; Cat. #a | MM/RP/GPb |
| cortactin | 421 | 80/85 | BioS; 44–854 | RP |
| paxillin | 31 | 68 | BioS; 44–720 | RP |
| paxillin | 118 | 68 | BioS; 44–722 | RP |
| Shc | 239/240 | 46, 52, 66 | BioS; 44–830 | RP |
| PKC-δ | 311 | 77 | BioS; 44–950 | RP |
| PLC-γ1 | 783 | 130 | Bios; 44–696 | RP |
| p56Dok-2 | 351 | 56, 58 | CS; 3911 | RP |
| CAS | 410 | 130 | CS; 4011 | RP |
| connexin-43 | 265 | 43 | SC; sc-17220 | GP |
| p120catenin | 228 | 120 | BD; 612536 | MM |
| vinculin | 100 | 130 | BioS; 44–1074G | RP |
| vinculin | 1065 | 130 | BioS; 44–1078G | RP |
| (B) Antibodies used for IP | ||||
| Substrate | Mol mass (kDa) | Co.; Cat. # a | MM/RP b | |
| Sam68 | 68 | SC; sc-333 | RP | |
| Annexin II (H-50) | 36(90) | SC; sc-9061 | RP | |
| p190Rho-GAP | 190 | BD; 610149 | MM | |
| Eps8 | 97 | BD; 610143 | MM | |
| Crk (Crk II) | 40 | BD; 610035 | MM | |
| (C) Antibodies used for total substrate protein level | ||||
| Substrate | Mol mass (kDa) | Co.; Cat. # a | MM/RP b | |
| cortactin | 80/85 | CS; 3502 | RP | |
| paxillin | 68 | BD; 610551 | MM | |
| Shc | 46, 52, 66 | CS; 2432 | RP | |
| PKC-δ | 77 | SC; sc-213 | RP | |
| PLC-γ1 | 130 | CS; 2822 | RP | |
| p56Dok-2 | 56, 58 | CS; 3914 | RP | |
| CAS | 130 | BD; 610271 | MM | |
| p120catenin | 120 | BD; 610133 | MM | |
| vinculin | 130 | Sigma; V-9131 | MM | |
| GAPDH | 37 | SC; sc-25778 | RP | |
| (D) Epitope-tag antibodies | ||||
| Epitope tag | Co.; Cat. # a | MM/RP b | ||
| GST | SC; sc-138 | MM | ||
| FLAG | Sigma; F3040 | MM | ||
| GFP | Invitrogen; A6455 | RP | ||
